Cantor Fitzgerald Predicts Elutia FY2025 Earnings

Elutia Inc. (NASDAQ:ELUT) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Elutia in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn anticipates that the company will post earnings per share of ($0.95) for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $10.00 price target on the stock. The consensus estimate for Elutia’s current full-year earnings is ($1.76) per share.

Elutia Price Performance

Elutia stock opened at $3.22 on Wednesday. Elutia has a 1 year low of $2.28 and a 1 year high of $5.24. The firm’s 50 day moving average price is $3.89 and its 200-day moving average price is $3.82. The stock has a market cap of $111.28 million, a P/E ratio of -1.23 and a beta of 0.89.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC lifted its position in shares of Elutia by 50.5% in the second quarter. Renaissance Technologies LLC now owns 53,616 shares of the company’s stock worth $266,000 after buying an additional 18,000 shares in the last quarter. Nantahala Capital Management LLC raised its holdings in shares of Elutia by 8.8% during the 2nd quarter. Nantahala Capital Management LLC now owns 1,795,697 shares of the company’s stock worth $8,907,000 after acquiring an additional 145,697 shares in the last quarter. Perkins Capital Management Inc. boosted its position in shares of Elutia by 9.8% during the 3rd quarter. Perkins Capital Management Inc. now owns 856,552 shares of the company’s stock valued at $3,263,000 after acquiring an additional 76,450 shares during the last quarter. Arcus Capital Partners LLC grew its holdings in shares of Elutia by 100.0% in the third quarter. Arcus Capital Partners LLC now owns 20,000 shares of the company’s stock valued at $76,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in Elutia by 50.3% in the third quarter. Geode Capital Management LLC now owns 188,408 shares of the company’s stock worth $718,000 after purchasing an additional 63,047 shares during the last quarter. Institutional investors own 74.03% of the company’s stock.

About Elutia

Elutia Inc, a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.